Genbei Wang

Genbei Wang is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of various medical conditions. With a total of two patents to his name, Wang's work focuses on innovative methods that enhance patient care and treatment efficacy.

Latest Patents

Wang's latest patents include a method of treating non-alcoholic steatohepatitis (NASH) using a long-acting mutant human fibroblast growth factor. This invention involves administering a long-acting mutant human fibroblast growth factor, specifically mPEG-CH—NH-mFGF21, to subjects in need of treatment. The second patent pertains to the application of andrographolide in the preparation of a pharmaceutical for treating inflammatory bowel disease. This invention includes an andrographolide enteric targeting micropellet and a method for its preparation, highlighting the uses of andrographolide in pharmaceutical applications.

Career Highlights

Throughout his career, Genbei Wang has worked with prominent companies in the biopharmaceutical sector, including Tasly Biopharmaceuticals Co., Ltd. and Tasly Pharmaceutical Group Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Wang has collaborated with notable colleagues, including Xiaohui Ma and Jian Li. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the pharmaceutical field.

Conclusion

Genbei Wang's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through inventive solutions. His patents reflect a deep understanding of medical needs and a dedication to advancing treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.